CLAP-seq: An Aptamer-Based Platform for Transcriptome-Wide Mapping of RNA Modifications
CLAP-seq:基于适配体的 RNA 修饰全转录组图谱平台
基本信息
- 批准号:9812571
- 负责人:
- 金额:$ 17.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-02 至 2021-08-01
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesBase PairingBindingBiologyChemicalsDNADataData SetDevelopmentDevelopmental ProcessDiseaseEngineeringEnsureEnzymesGenerationsGenetic TranscriptionGoalsHealthHumanHuman DevelopmentImageIn VitroIndividualKnowledgeLeadLinkMapsMethodsMissionModificationNational Institute of Child Health and Human DevelopmentNucleic AcidsNucleosidesNucleotidesOligonucleotidesPhysiologicalPost-Transcriptional RNA ProcessingPost-Translational Protein ProcessingPropertyProtocols documentationPublishingRNARNA BindingReadinessReagentReportingResearchResearch Project GrantsRiboseRoleRouteSiteSpecificityTechniquesTechnologyValidationaptamerbasechemical bindingcrosslinkenantiomerepitranscriptomeepitranscriptomicsfrontierhuman diseaseinnovationinnovative technologiesloss of functionnext generation sequencingnovelstereochemistrytranscriptome
项目摘要
Project Summary/Abstract
Beginning in the 1950s, more than 100 types of posttranscriptional modifications have been identified in
cellular RNA. Today, the study of RNA post-transcriptional modifications – known as epitranscriptomics – is a
rapidly developing field, which promises to greatly enhance our understanding of human health and disease.
Despite the profound implications already assigned to many RNA modifications, their precise functions remain
poorly understood. This can be attributed to the lack of sensitive and robust sequencing technologies to detect
these epitranscriptomics marks in a transcriptome-wide manner. A key bottleneck is the lack of sensitive and
specific enrichment techniques (affinity- or reactivity-based) for RNA molecules containing these modifications.
The proposed research takes direct aim at this critical deficit using the aptamer approach, employing in vitro
selection methods to identify nucleic acid molecules that bind chemically modified RNAs. These aptamers are
unique in that they are comprised of L-(deoxy)ribose-based nucleic acids (L-DNA and L-RNA), which are mirror
images (enantiomers) of natural D-nucleotides. L-Aptamers, which are completely orthogonal to natural biology,
are extremely well suited for binding RNA targets. Therefore, in vitro selection will be used to isolate novel L-
aptamers capable of binding chemically modified mononucleotides, which will enable selective capture of RNA
molecules containing the same modified residue. These L-aptamers will then be used in Cross-Linking-
Aptamer Pull-down and sequencing (CLAP-seq), the first transcriptome-wide profiling technology employing
aptamer-based RNA enrichment prior to next-generation sequencing. CLAP-seq not only promises to open a
general and robust route towards transcriptome-wide profiling of the growing list of RNA modifications, but also
promises to reinforce our current view of the epitranscriptome. Accordingly, the development of CLAP-seq will
have a profound impact on the field of epitranscriptomics, which is well aligned with the mission of the NICHD
and the goal of this FOA: to promote research into the role of RNA chemical modifications in development and
related disease.
项目总结/摘要
从20世纪50年代开始,已经鉴定了100多种类型的转录后修饰,
细胞RNA今天,RNA转录后修饰的研究-被称为表转录组学-是一项重要的研究。
这是一个快速发展的领域,有望大大提高我们对人类健康和疾病的理解。
尽管许多RNA修饰已经具有深刻的意义,但它们的精确功能仍然存在。
不太了解。这可归因于缺乏灵敏和稳健的测序技术来检测
这些表型转录组学标记以转录组范围的方式。一个关键的瓶颈是缺乏敏感和
特异性富集技术(基于亲和力或反应性)用于含有这些修饰的RNA分子。
拟议中的研究采用适体方法直接瞄准这一关键缺陷,
选择方法来鉴定结合化学修饰的RNA的核酸分子。这些适体是
其独特之处在于它们由基于L-(脱氧)核糖的核酸(L-DNA和L-RNA)组成,它们是镜像的。
天然D-核苷酸的图像(对映体)。L-适体,这是完全正交的自然生物学,
非常适合结合RNA靶点。因此,体外筛选将用于分离新的L-
能够结合化学修饰的单核苷酸的适体,其将能够选择性捕获RNA
含有相同修饰残基的分子。这些L-适体然后将用于交联-聚合。
适体下拉和测序(CLAP-seq),第一个转录组范围的分析技术,
在下一代测序之前进行基于适体的RNA富集。CLAP-seq不仅承诺打开一个
这是一种通用和强大的途径,可以对不断增长的RNA修饰列表进行全转录组分析,而且
有望加强我们目前对墓志铭的看法。因此,CLAP-seq的开发将
对表观转录组学领域产生了深远的影响,这与NICHD的使命是一致的
本FOA的目标是:促进研究RNA化学修饰在发育中的作用,
相关疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan Thomas Sczepanski其他文献
Jonathan Thomas Sczepanski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan Thomas Sczepanski', 18)}}的其他基金
An L-Aptamer-Displacement Assay for High-Throughput Screening of RNA-Targeted Small Molecule Antivirals
用于高通量筛选 RNA 靶向小分子抗病毒药物的 L 适体置换测定
- 批准号:
10648368 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
镜像适体:用于基础研究和治疗应用的下一代 RNA 结合试剂
- 批准号:
9382491 - 财政年份:2017
- 资助金额:
$ 17.76万 - 项目类别:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
镜像适体:用于基础研究和治疗应用的下一代 RNA 结合试剂
- 批准号:
10001546 - 财政年份:2017
- 资助金额:
$ 17.76万 - 项目类别:
Mirror Image Aptamers: Next Generation RNA-Binding Reagents for Basic Research and Therapeutic Applications
镜像适体:用于基础研究和治疗应用的下一代 RNA 结合试剂
- 批准号:
10240632 - 财政年份:2017
- 资助金额:
$ 17.76万 - 项目类别:
In vitro evolution of ribozymes capable of site-specific histone acetylation
能够进行位点特异性组蛋白乙酰化的核酶的体外进化
- 批准号:
8462476 - 财政年份:2012
- 资助金额:
$ 17.76万 - 项目类别:
In vitro evolution of ribozymes capable of site-specific histone acetylation
能够进行位点特异性组蛋白乙酰化的核酶的体外进化
- 批准号:
8308862 - 财政年份:2012
- 资助金额:
$ 17.76万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 17.76万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 17.76万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 17.76万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 17.76万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 17.76万 - 项目类别:














{{item.name}}会员




